Sean P. Brusky - 05 Mar 2026 Form 3 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: Chief Business Officer
Issuer ticker: PRLD
Reported as of: 05 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 19 Mar 2026, 19:39:30 UTC
Prior SEC filing: 03 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Bryant Lim, as attorney-in-fact for the Reporting Person

Key filing fact

Sean P. Brusky filed Form 3 for Prelude Therapeutics Inc (PRLD) on 19 Mar 2026.

Key facts

This page summarizes Sean P. Brusky's Form 3 filing for Prelude Therapeutics Inc (PRLD).
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 19 Mar 2026, 19:39.

Change

Previous filing in this sequence was filed on 03 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001884733 Primary reporting owner

Brusky Sean P.

Relationship: Chief Business Officer
Address: C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON
Signature: /s/ Bryant Lim, as attorney-in-fact for the Reporting Person
Signature date: 19 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRLD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100,000
Date: 05 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRLD holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $0.000000
Footnotes: F1

PRLD holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 175,000
Exercise price: $0.000000
Footnotes: F2

PRLD holding Derivative

Employee Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 275,000
Exercise price: $0.000000
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Stock option grant awarded on May 1, 2024 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on May 1, 2025, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F2

Stock option grant awarded on February 4, 2025 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2026, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F3

Stock option grant awarded on February 4, 2026 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2027, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC remarks

Exhibit 24 - Power of Attorney